Last reviewed 2026-05-15 · How we verify

Bupivicaine and Fentany

Cairo University · FDA-approved active Small molecule Quality 2/100

Bupivicaine and Fentany is a Small molecule drug developed by Cairo University. It is currently FDA-approved.

At a glance

Generic name	Bupivicaine and Fentany
Sponsor	Cairo University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Local and Intravenous Dexamethasone on Post Operative Pain a After CS (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bupivicaine and Fentany CI brief — competitive landscape report
Bupivicaine and Fentany updates RSS · CI watch RSS
Cairo University portfolio CI

Frequently asked questions about Bupivicaine and Fentany

What is Bupivicaine and Fentany?

Bupivicaine and Fentany is a Small molecule drug developed by Cairo University.

Who makes Bupivicaine and Fentany?

Bupivicaine and Fentany is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

What development phase is Bupivicaine and Fentany in?

Bupivicaine and Fentany is FDA-approved (marketed).

Manufacturer: Cairo University — full pipeline
Compare: Bupivicaine and Fentany vs similar drugs
Pricing: Bupivicaine and Fentany cost, discount & access